Work

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians

Year: 2020

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2020.07.002

Authors: V. Subbiah, D.B. Solit, T.A. Chan, R. Kurzrock

Institutions: The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Cleveland Clinic, Moores Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: National Institutes of Health

OpenAlex ID: W3047253098

FWCI: 12.91

Cites: 17

Cited by: 252

Related to: 10